Physician profile
Joseph Deblasio
NPI 1669544003
$4,321.07
in general payments reported to CMS, 2019-2025
21 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $270 · 2021: $715 · 2022: $952 · 2023: $1,017 · 2024: $597 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,806.84 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $468.11 | 2020-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $395.98 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Coloplast Corp | $97.56 | 2019 | |
| Lilly USA, LLC | $70.56 | 2021-2023 | Jardiance |
| Exact Sciences Corporation | $64.94 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $62.62 | 2021-2023 | |
| Astellas Pharma US INC | $60.50 | 2023 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $50.11 | 2022-2025 | |
| Abbott Laboratories | $49.05 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $29.13 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.62 | 2022-2023 | Synjardy, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $27.72 | 2021-2022 | |
| Dexcom, INC. | $19.05 | 2025 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $14.26 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Embecta Corp. | $13.68 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Amneal Pharmaceuticals LLC | $13.49 | 2022 | |
| Bausch Health US, LLC | $13.09 | 2022 | |
| Amarin Pharma, INC. | $13.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.39 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.36 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Deblasio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.